UniProt P51617 · PDB · AlphaFold · Substrate: MBP · Clone: aa 197-721high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Pacritinib | 99.6% | 0.4% | 88.64 | 0.452 |
| 2 | Abemaciclib | 98.3% | 1.7% | 91.48 | 0.563 |
| 3 | Ponatinib | 97.7% | 2.3% | 78.23 | 0.534 |
| 4 | Encorafenib | 97.5% | 2.5% | 98.50 | 0.755 |
| 5 | Crizotinib | 90.6% | 9.4% | 91.39 | 0.581 |
| 6 | Alectinib | 85.2% | 14.8% | 95.49 | 0.651 |
| 7 | Tepotinib | 72.6% | 27.4% | 99.75 | 0.727 |
| 8 | Afatinib | 72.1% | 27.9% | 98.50 | 0.709 |
| 9 | Sunitinib | 71.9% | 28.1% | 91.73 | 0.524 |
| 10 | Gilteritinib | 70.2% | 29.8% | 88.97 | 0.506 |
| 11 | Brigatinib | 62.9% | 37.1% | 82.96 | 0.513 |
| 12 | Gefitinib | 62.4% | 37.6% | 99.25 | 0.650 |
| 13 | Dacomitinib | 60.2% | 39.8% | 97.99 | 0.664 |
| 14 | Pirtobrutinib | 50.1% | 49.9% | 99.49 | 0.656 |
| 15 | Defactinib | 50.0% | 50.0% | 92.68 | 0.450 |
| 16 | Canertinib | 45.9% | 54.1% | 96.49 | 0.671 |
| 17 | Repotrectinib | 44.3% | 55.7% | 84.21 | 0.608 |
| 18 | Baricitinib | 32.9% | 67.1% | 97.99 | 0.616 |
| 19 | Neratinib | 29.3% | 70.7% | 93.18 | 0.597 |
| 20 | Fostamatinib | 28.5% | 71.5% | 96.74 | 0.613 |
Paralog block
IRAK1, IRAK4
EMT expression
- Mesenchymal log2(TPM+1): 6.58
- Epithelial log2(TPM+1): 6.49
- Fold change: 0.10
- Status: No significant change
High-confidence drugs
- Encorafenib — inh 97.5% · KISS 58.34
- Tepotinib — inh 72.6% · KISS 38.20
- Abemaciclib — inh 98.3% · KISS 35.61
Selectivity landscape vs inhibition on IRAK1
Each point is one of the 92 approved drugs; color = inhibition % on IRAK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…